title: Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
abstract: Dysregulation of microRNA let-7a-3 has been identified in several solid tumors and is associated with prognosis of patients. However, the pattern of let-7a-3 expression and the impact on prognosis has not yet been studied in acute myeloid leukemia (AML). The purpose of this study is to investigate the expression status of let-7a-3 and its clinical significance in AML patients using real-time quantitative PCR. Overexpression of let-7a-3 was identified in 25 of 102 (25%) de novo AML. There was no significant difference in age, blood parameters, FAB/WHO subtypes, karyotype risks and nine gene mutations (FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, C/EBPA and N/K-RAS) between patients with and without let-7a-3 overexpression (P>0.05). The patients with let-7a-3 overexpression had similar rates of complete remission (CR) as those without let-7a-3 overexpression (50% vs. 56%, P=0.693). Although the overall survival (OS) of AML patients with let-7a-3 overexpression (median 12 months,) was shorter than those without overexpression (median 25 months), the difference was not statistically significant (P=0.228). However, among those 51 obtained CR, patients with let-7a-3 overexpression had significantly shorter OS than those without let-7a-3 overexpression (P=0.029). The difference in relapse-free survival (RFS) was also significant between two groups (P=0.005). These findings suggest that let-7a-3 overexpression is a common event and is associated with poor clinical outcome in AML.
authors.affiliation: Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Li
authors.forename: Jiang
authors.initials: J
authors.lastname: Lin
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Jun
authors.initials: J
authors.lastname: Qian
authors.forename: Wei
authors.initials: W
authors.lastname: Qian
authors.forename: Dong-Ming
authors.initials: DM
authors.lastname: Yao
authors.forename: Zhao-Qun
authors.initials: ZQ
authors.lastname: Deng
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.forename: Xing-Xing
authors.initials: XX
authors.lastname: Chen
authors.forename: Dong
authors.initials: D
authors.lastname: Xie
authors.forename: Cui
authors.initials: C
authors.lastname: An
authors.forename: Chun-Yan
authors.initials: CY
authors.lastname: Tang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D000090243:Nucleophosmin; D011379:Prognosis; D016019:Survival Analysis; D015854:Up-Regulation / Q000235:genetics; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; C000716967:NPM1 protein, human; C487931:mirnlet7 microRNA, human; D000090243:Nucleophosmin
keywords: Acute myeloid leukemia; MicroRNA; Prognosis; let-7a-3